{"id": "article-17663_0", "title": "Anthracyclines -- Continuing Education Activity", "content": "Anthracyclines are drugs extracted from Streptomyces spp. and used to treat various types of cancers. These agents are among the most effective anticancer drugs to date. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of anthracycline therapy in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients with the various cancers for which they are indicated.", "contents": "Anthracyclines -- Continuing Education Activity. Anthracyclines are drugs extracted from Streptomyces spp. and used to treat various types of cancers. These agents are among the most effective anticancer drugs to date. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of anthracycline therapy in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients with the various cancers for which they are indicated."}
{"id": "article-17663_1", "title": "Anthracyclines -- Continuing Education Activity", "content": "Objectives: Summarize the indications for anthracycline therapy in a chemotherapeutic regimen. Identify the therapeutic mechanism of action of drugs in the anthracycline class. Outline the potential adverse events profile associated with anthracycline use. Review interprofessional team strategies for improving care coordination and communication to advance appropriate clinical outcomes with anthracycline chemotherapy for cancer treatment and drive optimal outcomes with the least adverse effects. Access free multiple choice questions on this topic.", "contents": "Anthracyclines -- Continuing Education Activity. Objectives: Summarize the indications for anthracycline therapy in a chemotherapeutic regimen. Identify the therapeutic mechanism of action of drugs in the anthracycline class. Outline the potential adverse events profile associated with anthracycline use. Review interprofessional team strategies for improving care coordination and communication to advance appropriate clinical outcomes with anthracycline chemotherapy for cancer treatment and drive optimal outcomes with the least adverse effects. Access free multiple choice questions on this topic."}
{"id": "article-17663_2", "title": "Anthracyclines -- Indications", "content": "Anthracyclines are drugs extracted from Streptomyces spp. used in the treatment of various types of cancers. The different types available for treatment are: Daunorubicin Doxorubicin Epirubicin Idarubicin Mitoxantrone Valrubicin Anthracyclines are among the most effective chemotherapy agents and cover a significant number of cancers. [1] FDA Approved Indications [2] [3] [4] Acute lymphocytic leukemia Acute myelogenous leukemia Hodgkin's lymphoma Non-Hodgkin's lymphoma Bladder cancer Rapidly recurrent (Ta or Ti) or in situ transitional cell carcinoma (Intravesical therapy) Neoadjuvant treatment Metastatic transitional cell bladder cancer Breast cancer Adjuvant therapy following axillary lymph node resection in primary breast cancer Neoadjuvant therapy Metastatic breast cancer Other metastatic cancers Ovarian cancer Osteogenic sarcoma Ewing sarcoma Soft tissue sarcoma Thyroid cancer Neuroblastoma Wilm's tumor Small cell lung cancer", "contents": "Anthracyclines -- Indications. Anthracyclines are drugs extracted from Streptomyces spp. used in the treatment of various types of cancers. The different types available for treatment are: Daunorubicin Doxorubicin Epirubicin Idarubicin Mitoxantrone Valrubicin Anthracyclines are among the most effective chemotherapy agents and cover a significant number of cancers. [1] FDA Approved Indications [2] [3] [4] Acute lymphocytic leukemia Acute myelogenous leukemia Hodgkin's lymphoma Non-Hodgkin's lymphoma Bladder cancer Rapidly recurrent (Ta or Ti) or in situ transitional cell carcinoma (Intravesical therapy) Neoadjuvant treatment Metastatic transitional cell bladder cancer Breast cancer Adjuvant therapy following axillary lymph node resection in primary breast cancer Neoadjuvant therapy Metastatic breast cancer Other metastatic cancers Ovarian cancer Osteogenic sarcoma Ewing sarcoma Soft tissue sarcoma Thyroid cancer Neuroblastoma Wilm's tumor Small cell lung cancer"}
{"id": "article-17663_3", "title": "Anthracyclines -- Indications -- Non-FDA Indications", "content": "Advanced endometrial carcinoma Metastatic hepatocellular cancer Multiple myeloma Advanced renal cell carcinoma (with sarcomatoid features) Thymomas and thymic malignancies Uterine sarcoma Waldenstrom macroglobulinemia Even though anthracyclines were discovered over 50 years ago, they still see a significant level of use in a number of types of cancers today. [5]", "contents": "Anthracyclines -- Indications -- Non-FDA Indications. Advanced endometrial carcinoma Metastatic hepatocellular cancer Multiple myeloma Advanced renal cell carcinoma (with sarcomatoid features) Thymomas and thymic malignancies Uterine sarcoma Waldenstrom macroglobulinemia Even though anthracyclines were discovered over 50 years ago, they still see a significant level of use in a number of types of cancers today. [5]"}
{"id": "article-17663_4", "title": "Anthracyclines -- Mechanism of Action", "content": "The explanations of cytostatic and cytotoxic actions of anthracyclines point to\u00a0a number of different mechanisms, including free radical formation, lipid peroxidation, direct membrane effects, and enzyme interactions. The following elucidates some of these theories:", "contents": "Anthracyclines -- Mechanism of Action. The explanations of cytostatic and cytotoxic actions of anthracyclines point to\u00a0a number of different mechanisms, including free radical formation, lipid peroxidation, direct membrane effects, and enzyme interactions. The following elucidates some of these theories:"}
{"id": "article-17663_5", "title": "Anthracyclines -- Mechanism of Action -- Enzyme Interaction", "content": "The most widely accepted explanation for the action of anthracyclines is their interaction with topoisomerase-II. The ternary complex thus formed prevents the re-ligation of the ds-DNA breaks. Subsequently, it promotes growth arrest and apoptotic cell death. [6]", "contents": "Anthracyclines -- Mechanism of Action -- Enzyme Interaction. The most widely accepted explanation for the action of anthracyclines is their interaction with topoisomerase-II. The ternary complex thus formed prevents the re-ligation of the ds-DNA breaks. Subsequently, it promotes growth arrest and apoptotic cell death. [6]"}
{"id": "article-17663_6", "title": "Anthracyclines -- Mechanism of Action -- DNA Intercalation", "content": "Anthracyclines have a chromophore moiety that has an intercalating function and inserts between adjacent base pairs of DNA when localized to the cell's nucleus; this inhibits DNA and RNA synthesis, especially in highly replicating cells blocking cell division. [6]", "contents": "Anthracyclines -- Mechanism of Action -- DNA Intercalation. Anthracyclines have a chromophore moiety that has an intercalating function and inserts between adjacent base pairs of DNA when localized to the cell's nucleus; this inhibits DNA and RNA synthesis, especially in highly replicating cells blocking cell division. [6]"}
{"id": "article-17663_7", "title": "Anthracyclines -- Mechanism of Action -- Reactive Oxygen Species (ROS)", "content": "Redox reactions generate reactive oxygen species in the presence of cytochrome P450 reductase, NADH dehydrogenase, and\u00a0xanthine oxidase. The excess ROS cannot be detoxified, resulting in oxidative stress, DNA damage, and lipid peroxidation triggering cell apoptosis. [6]", "contents": "Anthracyclines -- Mechanism of Action -- Reactive Oxygen Species (ROS). Redox reactions generate reactive oxygen species in the presence of cytochrome P450 reductase, NADH dehydrogenase, and\u00a0xanthine oxidase. The excess ROS cannot be detoxified, resulting in oxidative stress, DNA damage, and lipid peroxidation triggering cell apoptosis. [6]"}
{"id": "article-17663_8", "title": "Anthracyclines -- Mechanism of Action -- DNA Adduct Formation", "content": "These drugs are known to form adducts with DNA promoted by formaldehyde-releasing pro-drugs. The adducts block specific transcription factors and eventually initiate apoptosis. [6]", "contents": "Anthracyclines -- Mechanism of Action -- DNA Adduct Formation. These drugs are known to form adducts with DNA promoted by formaldehyde-releasing pro-drugs. The adducts block specific transcription factors and eventually initiate apoptosis. [6]"}
{"id": "article-17663_9", "title": "Anthracyclines -- Administration", "content": "Anthracyclines\u00a0administration is generally by injection or\u00a0via an intravenous infusion. The type of cancer and its stage will influence\u00a0the dose and duration of chemotherapy. As an example, treatment\u00a0may be daily for\u00a0two weeks followed by an off week to permit the\u00a0body to recover and regenerate new cells. This 3-week cycle may then be repeated.\u00a0There are\u00a0numerous time and administration sequences used; this one given is only an example.\u00a0Clinicians need to explain the administration process to the patient so they can understand the schedule, and also receive counsel on factors that may alter the administration regimen.", "contents": "Anthracyclines -- Administration. Anthracyclines\u00a0administration is generally by injection or\u00a0via an intravenous infusion. The type of cancer and its stage will influence\u00a0the dose and duration of chemotherapy. As an example, treatment\u00a0may be daily for\u00a0two weeks followed by an off week to permit the\u00a0body to recover and regenerate new cells. This 3-week cycle may then be repeated.\u00a0There are\u00a0numerous time and administration sequences used; this one given is only an example.\u00a0Clinicians need to explain the administration process to the patient so they can understand the schedule, and also receive counsel on factors that may alter the administration regimen."}
{"id": "article-17663_10", "title": "Anthracyclines -- Administration -- Mode of Administration", "content": "Injectable Intravenous Intraarterial - Not FDA approved for chemotherapy; used for hepatic artery chemoembolization Intravesical - Used in early bladder cancer", "contents": "Anthracyclines -- Administration -- Mode of Administration. Injectable Intravenous Intraarterial - Not FDA approved for chemotherapy; used for hepatic artery chemoembolization Intravesical - Used in early bladder cancer"}
{"id": "article-17663_11", "title": "Anthracyclines -- Administration -- Dosage", "content": "The dosing of anthracyclines is by body\u00a0surface area and varies with indication and type of anthracycline.\u00a0general dose ranges for anthracyclines are listed below; specific indications will vary the dose. Clinicians should consult facility-specific dosing regimens and consult package inserts for specific agents. The following shows the dosing regimens for doxorubicin, as an example of how agents in this class may be dosed and administered.", "contents": "Anthracyclines -- Administration -- Dosage. The dosing of anthracyclines is by body\u00a0surface area and varies with indication and type of anthracycline.\u00a0general dose ranges for anthracyclines are listed below; specific indications will vary the dose. Clinicians should consult facility-specific dosing regimens and consult package inserts for specific agents. The following shows the dosing regimens for doxorubicin, as an example of how agents in this class may be dosed and administered."}
{"id": "article-17663_12", "title": "Anthracyclines -- Administration -- Acute Lymphoblastic Leukemia", "content": "60 to 75 mg/m repeated every 21 days as a single agent 40 to 75 mg/m repeated every 21 days if combined with other chemotherapeutic agents Cumulative dose not to exceed 550 mg/m The dosing is the same for adults, adolescents, and children", "contents": "Anthracyclines -- Administration -- Acute Lymphoblastic Leukemia. 60 to 75 mg/m repeated every 21 days as a single agent 40 to 75 mg/m repeated every 21 days if combined with other chemotherapeutic agents Cumulative dose not to exceed 550 mg/m The dosing is the same for adults, adolescents, and children"}
{"id": "article-17663_13", "title": "Anthracyclines -- Administration -- Acute Myelogenous Leukemia", "content": "60 to 75 mg/m repeated every 21 days as a single agent 40 to 75 mg/m repeated every 21 days if combined with other chemotherapeutic agents Cumulative dose not to exceed 550 mg/m The dosing is the same for adults, adolescents, and\u00a0children", "contents": "Anthracyclines -- Administration -- Acute Myelogenous Leukemia. 60 to 75 mg/m repeated every 21 days as a single agent 40 to 75 mg/m repeated every 21 days if combined with other chemotherapeutic agents Cumulative dose not to exceed 550 mg/m The dosing is the same for adults, adolescents, and\u00a0children"}
{"id": "article-17663_14", "title": "Anthracyclines -- Administration -- Hodgkin Lymphoma", "content": "Stanford V regimen 25 mg/m^2 on weeks 1,3,5,7,9, and 11 in combination with mechlorethamine, vinblastine, vincristine, bleomycin, and prednisone. The total duration of treatment is 12 weeks BEACOPP regimen Adults and adolescents 15 years or older: 25 mg/m on day 1 in combination with bleomycin, etoposide, cyclophosphamide, vincristine, procarbazine, and prednisone ABVD/MOPP regimen 25 mg/m^2 on days 1 and 15 repeated every 28 days in combination with vinblastine, bleomycin, and dacarbazine It is also used with vinblastine, brentuximab vedotin, and dacarbazine as well. The dosing is the same for adults, adolescents, and\u00a0children", "contents": "Anthracyclines -- Administration -- Hodgkin Lymphoma. Stanford V regimen 25 mg/m^2 on weeks 1,3,5,7,9, and 11 in combination with mechlorethamine, vinblastine, vincristine, bleomycin, and prednisone. The total duration of treatment is 12 weeks BEACOPP regimen Adults and adolescents 15 years or older: 25 mg/m on day 1 in combination with bleomycin, etoposide, cyclophosphamide, vincristine, procarbazine, and prednisone ABVD/MOPP regimen 25 mg/m^2 on days 1 and 15 repeated every 28 days in combination with vinblastine, bleomycin, and dacarbazine It is also used with vinblastine, brentuximab vedotin, and dacarbazine as well. The dosing is the same for adults, adolescents, and\u00a0children"}
{"id": "article-17663_15", "title": "Anthracyclines -- Administration -- Intravesical", "content": "Rapidly recurrent (stage Ta or T1) or in situ transitional cell bladder cancer 50 to 150 mg\u00a0 in 150 ml of normal saline is instilled into the bladder and retained for at least 30 minutes", "contents": "Anthracyclines -- Administration -- Intravesical. Rapidly recurrent (stage Ta or T1) or in situ transitional cell bladder cancer 50 to 150 mg\u00a0 in 150 ml of normal saline is instilled into the bladder and retained for at least 30 minutes"}
{"id": "article-17663_16", "title": "Anthracyclines -- Adverse Effects", "content": "Although anthracyclines are among the most widely used chemotherapeutic agents, their therapeutic potential is limited by their extensive\u00a0adverse\u00a0event profile, ranging\u00a0from mild to severe. The incidence rates of these reactions, however, are largely unknown. [7] [8]", "contents": "Anthracyclines -- Adverse Effects. Although anthracyclines are among the most widely used chemotherapeutic agents, their therapeutic potential is limited by their extensive\u00a0adverse\u00a0event profile, ranging\u00a0from mild to severe. The incidence rates of these reactions, however, are largely unknown. [7] [8]"}
{"id": "article-17663_17", "title": "Anthracyclines -- Adverse Effects -- Mild", "content": "Chills - Rapid Urticaria - Rapid Pruritis - Rapid Injection site reaction - Rapid Rash\u00a0-\u00a0 Early Infection -\u00a0 Early Nausea and vomiting\u00a0-\u00a0 Early Fever\u00a0-\u00a0 Early Diarrhea\u00a0-\u00a0 Early Abdominal pain\u00a0-\u00a0 Early Urine discoloration\u00a0-\u00a0 Early Lacrimation\u00a0-\u00a0 Early Malaise\u00a0-\u00a0 Early Anorexia - Delayed Photosensitivity\u00a0- Delayed Nail discoloration\u00a0- Delayed Skin hyperpigmentation\u00a0- Delayed Amenorrhea\u00a0- Delayed Oligospermia\u00a0- Delayed Azoospermia\u00a0- Delayed Gonadal suppression\u00a0- Delayed Spermatogenesis inhibition\u00a0- Delayed Asthenia\u00a0- Delayed Co-enzyme Q10 deficiency\u00a0- Delayed", "contents": "Anthracyclines -- Adverse Effects -- Mild. Chills - Rapid Urticaria - Rapid Pruritis - Rapid Injection site reaction - Rapid Rash\u00a0-\u00a0 Early Infection -\u00a0 Early Nausea and vomiting\u00a0-\u00a0 Early Fever\u00a0-\u00a0 Early Diarrhea\u00a0-\u00a0 Early Abdominal pain\u00a0-\u00a0 Early Urine discoloration\u00a0-\u00a0 Early Lacrimation\u00a0-\u00a0 Early Malaise\u00a0-\u00a0 Early Anorexia - Delayed Photosensitivity\u00a0- Delayed Nail discoloration\u00a0- Delayed Skin hyperpigmentation\u00a0- Delayed Amenorrhea\u00a0- Delayed Oligospermia\u00a0- Delayed Azoospermia\u00a0- Delayed Gonadal suppression\u00a0- Delayed Spermatogenesis inhibition\u00a0- Delayed Asthenia\u00a0- Delayed Co-enzyme Q10 deficiency\u00a0- Delayed"}
{"id": "article-17663_18", "title": "Anthracyclines -- Adverse Effects -- Moderate", "content": "Bleeding - Early Bone marrow suppression\u00a0- Delayed Neutropenia\u00a0- Delayed Dehydration\u00a0- Delayed Stomatitis\u00a0- Delayed Esophagitis\u00a0- Delayed Colitis\u00a0- Delayed Erythema\u00a0- Delayed Palmar-plantar erythrodysesthesia\u00a0- Delayed Conjunctivitis\u00a0- Delayed Phlebitis\u00a0- Delayed Skin ulcer\u00a0- Delayed Radiation recall reaction\u00a0- Delayed Skin ulcer\u00a0- Delayed Elevated hepatic enzymes\u00a0- Delayed Peripheral neuropathy\u00a0- Delayed", "contents": "Anthracyclines -- Adverse Effects -- Moderate. Bleeding - Early Bone marrow suppression\u00a0- Delayed Neutropenia\u00a0- Delayed Dehydration\u00a0- Delayed Stomatitis\u00a0- Delayed Esophagitis\u00a0- Delayed Colitis\u00a0- Delayed Erythema\u00a0- Delayed Palmar-plantar erythrodysesthesia\u00a0- Delayed Conjunctivitis\u00a0- Delayed Phlebitis\u00a0- Delayed Skin ulcer\u00a0- Delayed Radiation recall reaction\u00a0- Delayed Skin ulcer\u00a0- Delayed Elevated hepatic enzymes\u00a0- Delayed Peripheral neuropathy\u00a0- Delayed"}
{"id": "article-17663_19", "title": "Anthracyclines -- Adverse Effects -- Severe", "content": "Anaphylactoid reactions\u00a0-\u00a0Rapid Tissue necrosis - Early Coma - Early Leukopenia\u00a0- Delayed Thrombocytopenia\u00a0- Delayed Heart Failure\u00a0- Delayed Cardiomyopathy\u00a0- Delayed Cardiotoxicity\u00a0- Delayed Pericarditis\u00a0- Delayed Myocarditis\u00a0- Delayed Typhlitis\u00a0- Delayed Peptic ulcer\u00a0- Delayed GI bleeding\u00a0- Delayed Keratitis\u00a0- Delayed Tumor lysis syndrome\u00a0- Delayed New primary malignancy\u00a0- Delayed Seizures\u00a0- Delayed", "contents": "Anthracyclines -- Adverse Effects -- Severe. Anaphylactoid reactions\u00a0-\u00a0Rapid Tissue necrosis - Early Coma - Early Leukopenia\u00a0- Delayed Thrombocytopenia\u00a0- Delayed Heart Failure\u00a0- Delayed Cardiomyopathy\u00a0- Delayed Cardiotoxicity\u00a0- Delayed Pericarditis\u00a0- Delayed Myocarditis\u00a0- Delayed Typhlitis\u00a0- Delayed Peptic ulcer\u00a0- Delayed GI bleeding\u00a0- Delayed Keratitis\u00a0- Delayed Tumor lysis syndrome\u00a0- Delayed New primary malignancy\u00a0- Delayed Seizures\u00a0- Delayed"}
{"id": "article-17663_20", "title": "Anthracyclines -- Adverse Effects", "content": "Researchers are studying ways to mitigate the toxicity of anthracyclines through newer technologies, including nanoparticle delivery systems. [5] [9] [10] The effectiveness of cardioprotective agents remains ambiguous; there is no high-quality evidence supporting their effectiveness. [10]", "contents": "Anthracyclines -- Adverse Effects. Researchers are studying ways to mitigate the toxicity of anthracyclines through newer technologies, including nanoparticle delivery systems. [5] [9] [10] The effectiveness of cardioprotective agents remains ambiguous; there is no high-quality evidence supporting their effectiveness. [10]"}
{"id": "article-17663_21", "title": "Anthracyclines -- Contraindications -- Relative Contraindications", "content": "Anthracycline hypersensitivity Patients with previous anaphylactic reactions following administration of anthracyclines Hepatic disease Patients with severe hepatic disease, defined as Child-Pugh class C or serum bilirubin greater than 5 mg/dL. Dosage adjustments are necessary for patients with mild to moderate hepatic\u00a0disease. Pre-existing cardiac conditions Heart failure, cardiomyopathy, myocardial infarction, myocarditis, pericarditis Assessment of cardiac function using a MUGA or echocardiogram is necessary before starting treatment in these patients. Gender Females have a higher risk of anthracycline-induced cardiotoxicity Age Children and adolescents have a higher risk of developing late cardiovascular dysfunction. They should receive periodic cardiac evaluations. Reports of prepubertal growth inhibition/failure and gonadal impairment in children and adolescents Pregnancy (category D) In animal studies Breastfeeding Live vaccines", "contents": "Anthracyclines -- Contraindications -- Relative Contraindications. Anthracycline hypersensitivity Patients with previous anaphylactic reactions following administration of anthracyclines Hepatic disease Patients with severe hepatic disease, defined as Child-Pugh class C or serum bilirubin greater than 5 mg/dL. Dosage adjustments are necessary for patients with mild to moderate hepatic\u00a0disease. Pre-existing cardiac conditions Heart failure, cardiomyopathy, myocardial infarction, myocarditis, pericarditis Assessment of cardiac function using a MUGA or echocardiogram is necessary before starting treatment in these patients. Gender Females have a higher risk of anthracycline-induced cardiotoxicity Age Children and adolescents have a higher risk of developing late cardiovascular dysfunction. They should receive periodic cardiac evaluations. Reports of prepubertal growth inhibition/failure and gonadal impairment in children and adolescents Pregnancy (category D) In animal studies Breastfeeding Live vaccines"}
{"id": "article-17663_22", "title": "Anthracyclines -- Monitoring -- Adults, Adolescents and, Children", "content": "Doxorubicin - Maximum lifetime cumulative dose of 550 mg/m; 450 mg/m^2 in patients who have received previous mediastinal radiation Daunorubicin - 45 mg/m/dose IV (up to\u00a090 mg/m/dose has been used off-label);\u00a0Maximum lifetime cumulative dose of 550 mg/m^2; 450 mg/m^2 in patients who have received previous mediastinal radiation. Epirubicin - 150 mg/m/dose\u00a0 as a single agent - maximum cumulative dose is\u00a0 900mg/m^2. Valrubicin - 800 mg intravesically in adults - efficacy and safety not established in adolescents and children Idarubicin - 12 mg/m^2 IV; maximum cumulative\u00a0 lifetime dose is 150 mg/m^2 - efficacy and safety not established in adolescents and children Mitoxantrone - Maximum cumulative lifetime dosage is 140 mg/m^2", "contents": "Anthracyclines -- Monitoring -- Adults, Adolescents and, Children. Doxorubicin - Maximum lifetime cumulative dose of 550 mg/m; 450 mg/m^2 in patients who have received previous mediastinal radiation Daunorubicin - 45 mg/m/dose IV (up to\u00a090 mg/m/dose has been used off-label);\u00a0Maximum lifetime cumulative dose of 550 mg/m^2; 450 mg/m^2 in patients who have received previous mediastinal radiation. Epirubicin - 150 mg/m/dose\u00a0 as a single agent - maximum cumulative dose is\u00a0 900mg/m^2. Valrubicin - 800 mg intravesically in adults - efficacy and safety not established in adolescents and children Idarubicin - 12 mg/m^2 IV; maximum cumulative\u00a0 lifetime dose is 150 mg/m^2 - efficacy and safety not established in adolescents and children Mitoxantrone - Maximum cumulative lifetime dosage is 140 mg/m^2"}
{"id": "article-17663_23", "title": "Anthracyclines -- Monitoring -- Drug Interactions", "content": "Anthracyclines are major substrates of CYP2D6 and CYP3A4.\u00a0Caution is necessary when using them concurrently with inhibitors of CYP3A4 and CYP2D6, as this will reduce anthracycline clearance and increase the chances of cardiotoxicity and other adverse effects. Notable interactions exist with taxanes (except docetaxel) and trastuzumab. [11] [12]", "contents": "Anthracyclines -- Monitoring -- Drug Interactions. Anthracyclines are major substrates of CYP2D6 and CYP3A4.\u00a0Caution is necessary when using them concurrently with inhibitors of CYP3A4 and CYP2D6, as this will reduce anthracycline clearance and increase the chances of cardiotoxicity and other adverse effects. Notable interactions exist with taxanes (except docetaxel) and trastuzumab. [11] [12]"}
{"id": "article-17663_24", "title": "Anthracyclines -- Toxicity -- Anthracycline-Induced Cardiotoxicity", "content": "Cardiotoxicity-induced by anthracyclines is a significant cause of morbidity and mortality. The clinical definition is new-onset heart failure and/or detection of left ventricular dysfunction in exposed individuals; LV ejection fraction is the most commonly used measure. [13] Patients at high risk are those receiving any of the following treatments - High dose anthracyclines (e.g., doxorubicin greater than 250 mg/m), high dose radiation therapy (greater than 30 Gy) where the heart is in the radiation field and, lower dose anthracyclines in combination with lower-dose radiation therapy. Other risk factors - Age older than 60 years at cancer diagnosis, compromised cardiac function, multiple cardiovascular risk factors including smoking, hypertension, hyperlipidemia and, obesity. [13]", "contents": "Anthracyclines -- Toxicity -- Anthracycline-Induced Cardiotoxicity. Cardiotoxicity-induced by anthracyclines is a significant cause of morbidity and mortality. The clinical definition is new-onset heart failure and/or detection of left ventricular dysfunction in exposed individuals; LV ejection fraction is the most commonly used measure. [13] Patients at high risk are those receiving any of the following treatments - High dose anthracyclines (e.g., doxorubicin greater than 250 mg/m), high dose radiation therapy (greater than 30 Gy) where the heart is in the radiation field and, lower dose anthracyclines in combination with lower-dose radiation therapy. Other risk factors - Age older than 60 years at cancer diagnosis, compromised cardiac function, multiple cardiovascular risk factors including smoking, hypertension, hyperlipidemia and, obesity. [13]"}
{"id": "article-17663_25", "title": "Anthracyclines -- Toxicity -- Antidotes for Anthracyclines", "content": "Tissue necrosis induced by the extravasation of anthracycline can have many complications. Dexrazoxane is an available antidote to tackle the effects of extravasation and may also help prevent the development of anthracycline-induced cardiotoxicity. [14] [15]", "contents": "Anthracyclines -- Toxicity -- Antidotes for Anthracyclines. Tissue necrosis induced by the extravasation of anthracycline can have many complications. Dexrazoxane is an available antidote to tackle the effects of extravasation and may also help prevent the development of anthracycline-induced cardiotoxicity. [14] [15]"}
{"id": "article-17663_26", "title": "Anthracyclines -- Enhancing Healthcare Team Outcomes", "content": "The administration of anthracyclines requires the efficient functioning of an interprofessional healthcare team comprised of doctors and other health professionals. A general practitioner, oncologist, physician assistant or nurse practitioner, pharmacist, and nurses are usually involved in the patient's care. A pediatrician and cardiologist may also have involvement as the case may dictate. The primary oncologist usually decides the patient's treatment plan;\u00a0they will also counsel the patient on the need for this chemotherapeutic agent and the potential risks. During the initial treatment phase, a pharmacist is usually involved in providing the patient information on the dose, adverse effects, monitoring, checking for possible drug interactions, and follow-up.", "contents": "Anthracyclines -- Enhancing Healthcare Team Outcomes. The administration of anthracyclines requires the efficient functioning of an interprofessional healthcare team comprised of doctors and other health professionals. A general practitioner, oncologist, physician assistant or nurse practitioner, pharmacist, and nurses are usually involved in the patient's care. A pediatrician and cardiologist may also have involvement as the case may dictate. The primary oncologist usually decides the patient's treatment plan;\u00a0they will also counsel the patient on the need for this chemotherapeutic agent and the potential risks. During the initial treatment phase, a pharmacist is usually involved in providing the patient information on the dose, adverse effects, monitoring, checking for possible drug interactions, and follow-up."}
{"id": "article-17663_27", "title": "Anthracyclines -- Enhancing Healthcare Team Outcomes", "content": "After the initial phase of treatment, the patient is regularly followed up in the oncology clinic by the oncologist, who assesses response to treatment and also monitors the patient for adverse effects. The oncologist may alternate with the physician assistant or the nurse practitioner to see the patient at shorter intervals. A pediatrician may monitor growth and development in cases of chemotherapy in children. Oncology certified nursing will administer the medication and must be aware of the signs of toxicity or adverse effects so they can effectively monitor the patient and report any issues to the clinician on duty or oncologist. These examples demonstrate the impact of an interprofessional team on patient care, driving outcomes to a positive result while minimizing adverse events.", "contents": "Anthracyclines -- Enhancing Healthcare Team Outcomes. After the initial phase of treatment, the patient is regularly followed up in the oncology clinic by the oncologist, who assesses response to treatment and also monitors the patient for adverse effects. The oncologist may alternate with the physician assistant or the nurse practitioner to see the patient at shorter intervals. A pediatrician may monitor growth and development in cases of chemotherapy in children. Oncology certified nursing will administer the medication and must be aware of the signs of toxicity or adverse effects so they can effectively monitor the patient and report any issues to the clinician on duty or oncologist. These examples demonstrate the impact of an interprofessional team on patient care, driving outcomes to a positive result while minimizing adverse events."}
{"id": "article-17663_28", "title": "Anthracyclines -- Enhancing Healthcare Team Outcomes", "content": "The most critical component of an interprofessional approach is the involvement of a cardiovascular team in the treatment to prevent anthracycline-induced\u00a0cardiotoxicity and manage it effectively. Several studies have shown the benefit of this approach, including long-term care and follow-up in the outpatient setting. One such study provides high-level evidence for the development of guidelines. [16] Interprofessional care coordination will derive the best patient outcome while minimizing the not insignificant potential adverse events of anthracycline therapy. [Level 5]", "contents": "Anthracyclines -- Enhancing Healthcare Team Outcomes. The most critical component of an interprofessional approach is the involvement of a cardiovascular team in the treatment to prevent anthracycline-induced\u00a0cardiotoxicity and manage it effectively. Several studies have shown the benefit of this approach, including long-term care and follow-up in the outpatient setting. One such study provides high-level evidence for the development of guidelines. [16] Interprofessional care coordination will derive the best patient outcome while minimizing the not insignificant potential adverse events of anthracycline therapy. [Level 5]"}
{"id": "article-17663_29", "title": "Anthracyclines -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Anthracyclines -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}